[Gene therapy in rheumatoid polyarthritis: perspectives]

Area of Science:

• Molecular Biology
• Immunology
• Biotechnology

Context:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic inflammation and joint destruction.
• Current RA treatments aim to manage symptoms and slow disease progression, but a significant unmet need for disease-modifying therapies remains.
• Gene therapy presents a potential new strategy for RA by targeting the underlying genetic and molecular mechanisms of the disease.

Purpose:

• To explore the application of gene therapy for rheumatoid arthritis (RA).
• To identify potential therapeutic gene targets involved in inflammation and joint destruction in RA.
• To discuss the role of viral and nonviral vectors in gene delivery for RA treatment.

Summary:

• Gene therapy involves in vivo insertion of genetic material to produce therapeutic molecules, currently in preliminary human feasibility studies.
• In RA models, target genes include those encoding inflammation inhibitors (e.g., IL-1 receptor antagonists) and joint-protective molecules (e.g., metalloprotease inhibitors).
• Effective gene therapy for RA necessitates advancements in vector technology and strategic decisions regarding transfection site (articular vs. systemic).

Impact:

• Gene therapy holds promise for developing innovative treatments for rheumatoid arthritis.
• Successful gene therapy could lead to more targeted and potentially curative approaches for RA, reducing joint damage and inflammation.
• Further research into gene targets, vectors, and delivery methods is crucial for translating gene therapy into clinical practice for RA.